These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3125744)

  • 21. Topical aldose reductase inhibitor.
    Coster D
    Br J Ophthalmol; 1995 Dec; 79(12):1064-5. PubMed ID: 8562535
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008].
    Tasaka H; Akagi Y; Yoshikawa T; Ikebe H; Takahashi Y; Chamoto K; Miyamoto Y; Terubayashi H
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):246-53. PubMed ID: 3111200
    [No Abstract]   [Full Text] [Related]  

  • 23. Corneal permeability of aldose reductase inhibitor, M79175. I. In vitro study using corneal permeability apparatus.
    Kato A; Ishibashi Y; Miyake Y; Iwata S
    J Ocul Pharmacol; 1986; 2(3):279-86. PubMed ID: 3139808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldose reductase inhibitors and diabetic complications.
    Raskin P; Rosenstock J
    Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
    [No Abstract]   [Full Text] [Related]  

  • 25. NIH conference. Aldose reductase and complications of diabetes.
    Cogan DG; Kinoshita JH; Kador PF; Robison G; Datilis MB; Cobo LM; Kupfer C
    Ann Intern Med; 1984 Jul; 101(1):82-91. PubMed ID: 6203454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients.
    Eaton RP; Sibbitt WL; Harsh A
    JAMA; 1985 Mar; 253(10):1437-40. PubMed ID: 3918180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
    Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
    J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
    [No Abstract]   [Full Text] [Related]  

  • 30. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of aldose reductase inhibitors.
    Zimmerman BR
    Diabetes Care; 1987; 10(1):123-5. PubMed ID: 3105984
    [No Abstract]   [Full Text] [Related]  

  • 32. Diabetic complications in the cornea.
    Ljubimov AV
    Vision Res; 2017 Oct; 139():138-152. PubMed ID: 28404521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 36. Photo-stabilization and solubilization of an aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodani ne (ONO-2235), by human serum albumin.
    Kurono Y; Furukawa A; Takesue Y; Li FL; Ikeda K
    Chem Pharm Bull (Tokyo); 1987 Jul; 35(7):3045-8. PubMed ID: 3119240
    [No Abstract]   [Full Text] [Related]  

  • 37. Current progress in clinical trials of aldose reductase inhibitors in Japan.
    Hotta N; Kakuta H; Ando F; Sakamoto N
    Exp Eye Res; 1990 Jun; 50(6):625-8. PubMed ID: 2115451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing wave-like epitheliopathy. Clinical features and treatment.
    D'Aversa G; Luchs JL; Fox MJ; Rosenbaum PS; Udell IJ
    Ophthalmology; 1997 Jun; 104(6):962-9. PubMed ID: 9186437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment.
    Meyer LA; Ubels JL; Edelhauser HF
    Invest Ophthalmol Vis Sci; 1988 Jun; 29(6):940-8. PubMed ID: 2967259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.